Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411522/ |
| id |
pubmed-3411522 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-34115222012-08-09 Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? Nasrallah, Sami N. Reynolds, L. Raymond Concise Review The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared to its rival basal insulin analogs, a longer duration of action and lower incidence of hypoglycemic events in both type 1 and type 2 diabetic patients has been demonstrated.1,2 Its unique mechanism of action is based on multihexamer formation after subcutaneous injection. This reportedly allows for less pharmacodynamic variability and within-subject variability than currently available insulin analogs, and a duration of action that is over 24 hours.3 The lack of proof of carcinogenicity with insulin degludec is yet another factor that would be taken into consideration when choosing the optimal basal insulin for a diabetic individual.4 A formulation of insulin degludec with insulin aspart, Insulin degludec 70%/aspart 30%, may permit improved flexibly of dosing without compromising glycemic control or safety.5 Libertas Academica 2012-04-11 /pmc/articles/PMC3411522/ /pubmed/22879797 http://dx.doi.org/10.4137/CMED.S9494 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Nasrallah, Sami N. Reynolds, L. Raymond |
| spellingShingle |
Nasrallah, Sami N. Reynolds, L. Raymond Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? |
| author_facet |
Nasrallah, Sami N. Reynolds, L. Raymond |
| author_sort |
Nasrallah, Sami N. |
| title |
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? |
| title_short |
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? |
| title_full |
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? |
| title_fullStr |
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? |
| title_full_unstemmed |
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? |
| title_sort |
insulin degludec, the new generation basal insulin or just another basal insulin? |
| description |
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared to its rival basal insulin analogs, a longer duration of action and lower incidence of hypoglycemic events in both type 1 and type 2 diabetic patients has been demonstrated.1,2 Its unique mechanism of action is based on multihexamer formation after subcutaneous injection. This reportedly allows for less pharmacodynamic variability and within-subject variability than currently available insulin analogs, and a duration of action that is over 24 hours.3 The lack of proof of carcinogenicity with insulin degludec is yet another factor that would be taken into consideration when choosing the optimal basal insulin for a diabetic individual.4 A formulation of insulin degludec with insulin aspart, Insulin degludec 70%/aspart 30%, may permit improved flexibly of dosing without compromising glycemic control or safety.5 |
| publisher |
Libertas Academica |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411522/ |
| _version_ |
1611547502763311104 |